What is BCAX (BCAX) stock price today?

BCAX (BCAX) is currently trading at $27.81, up 2.92% today.

What is BCAX P/E ratio?

BCAX's P/E ratio is -7.37. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BCAX return on equity (ROE)?

BCAX's return on equity (ROE) is -32.34%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is BCAX's market cap?

BCAX has a market capitalization of $1.52B.

NGM · Biotechnology

BCAX (BCAX) Stock

$27.81 +2.92% NGM: BCAX Healthcare

Valuation

Metric	Value
Price	$27.81
Market Cap	$1.52B
P/E Ratio	-7.37
P/B Ratio	2.64
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$30.72
52-Week Low	$7.80
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-32.34%
ROA	-21.09%
ROCE	-38.76%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	13.85

Annual Financials (USD)

Metric	2022	2023	2024	2025
Revenue	$0	$0	$0	$0
Operating Profit	$-38.0M	$-40.0M	$-82.0M	$-156.0M
Net Profit	$-38.0M	$-52.0M	$-68.0M	$-138.0M
EPS	$-0.73	$-1.00	$-1.25	$-2.52
Op Margin	—	—	—	—

Balance Sheet (USD)

Metric	2022	2023	2024	2025
Total Assets	$7.0M	$234.0M	$569.0M	$431.0M
Total Liabilities	$24.0M	$15.0M	$77.0M	$30.0M
Cash	$4.0M	$230.0M	$490.0M	$97.0M
Borrowings	$0	$1.0M	$1.0M	$2.0M

Latest News

Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing MT Newswires · Jul 10, 2026 Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? Motley Fool · Jun 13, 2026 Bicara (BCAX) Q4 2025 Earnings Transcript Motley Fool · Jun 1, 2026 Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer MarketBeat · May 22, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025
Operating Cash Flow	$-32.0M	$-46.0M	$-75.0M	$-107.0M
Investing Cash Flow	$0	$-1.0M	$0	$-319.0M
Financing Cash Flow	$0	$0	$2.0M	$0
Net Cash Flow	$-1.0M	$226.0M	$259.0M	$-393.0M
Free Cash Flow	$-32.0M	$-46.0M	$-75.0M	$-107.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.13
EV / EBITDA	-4.72
FCF Yield	-9.51%
Quick Ratio	13.85
Interest Coverage	—
Return 1Y	135.20%
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
EYPT	$12.41	+1.80%	-4.34	$1.04B	0.00%
FTRE	$18.43	+4.18%	-1.26	$1.75B	0.00%
KURA	$9.57	+3.13%	-2.90	$849.57M	0.00%
MRVI	$6.90	+3.06%	-4.48	$1.90B	0.00%
PHATPhathom Pharmaceuticals, Inc.	$11.81	+3.21%	-5.40	$941.68M	0.00%

About BCAX

BCAX is led by CEO Claire Mazumdar Clemon, employs 55 people, headquartered in US, publicly traded since 2024.

BCAX stock trades at $27.81 with a market capitalization of $1.52B. The stock is valued at a price-to-earnings (P/E) ratio of -7.37, price-to-book of 2.64, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.80 and $30.72, and currently trades 9.5% below its 52-week high.

On profitability, BCAX generates a return on equity (ROE) of -32.34%, return on capital employed of -38.76%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides